Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (neutrophils) | 0.10 |
| chemistry Open Targets | compounds already reach it: quisovalimab, baminercept | 0.81 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 4 Parkinson's papers of 399 | 0.79 |
| pathways Reactome | 3 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 8765
Sealed predictions
- TNFSF14 in dopamine neurons, braak-0.23 (p 0.551) → +0.09 (p 0.820)receipt 8771
Swarm cases
receipt 8771: TNFSF14 in dopamine neurons, braak
- power
- full sample -0.02 (p 0.942, n 18), 95% CI -0.48 to +0.45. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.01 (p 0.969, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.21 (p 0.393, n 18). could be the mix.
- skeptic
- leave-one-out range -0.14 to +0.10, sign flips 6; without severely affected donors -0.02 (p 0.942, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for TNFSF14 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts